Literature DB >> 22089420

Choline metabolism in malignant transformation.

Kristine Glunde1, Zaver M Bhujwalla, Sabrina M Ronen.   

Abstract

Abnormal choline metabolism is emerging as a metabolic hallmark that is associated with oncogenesis and tumour progression. Following transformation, the modulation of enzymes that control anabolic and catabolic pathways causes increased levels of choline-containing precursors and breakdown products of membrane phospholipids. These increased levels are associated with proliferation, and recent studies emphasize the complex reciprocal interactions between oncogenic signalling and choline metabolism. Because choline-containing compounds are detected by non-invasive magnetic resonance spectroscopy (MRS), increased levels of these compounds provide a non-invasive biomarker of transformation, staging and response to therapy. Furthermore, enzymes of choline metabolism, such as choline kinase, present novel targets for image-guided cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089420      PMCID: PMC4337883          DOI: 10.1038/nrc3162

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  186 in total

1.  Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method.

Authors:  R Katz-Brull; H Degani
Journal:  Anticancer Res       Date:  1996 May-Jun       Impact factor: 2.480

Review 2.  CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane.

Authors:  Suzanne Jackowski; Paolo Fagone
Journal:  J Biol Chem       Date:  2004-11-09       Impact factor: 5.157

3.  A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis.

Authors:  Roger B Sher; Chieko Aoyama; Kimberly A Huebsch; Shaonin Ji; Janos Kerner; Yan Yang; Wayne N Frankel; Charles L Hoppel; Philip A Wood; Dennis E Vance; Gregory A Cox
Journal:  J Biol Chem       Date:  2005-12-21       Impact factor: 5.157

4.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Authors:  Nada M S Al-Saffar; L Elizabeth Jackson; Florence I Raynaud; Paul A Clarke; Ana Ramírez de Molina; Juan C Lacal; Paul Workman; Martin O Leach
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  Expression and characterization of the active molecular forms of choline/ethanolamine kinase-alpha and -beta in mouse tissues, including carbon tetrachloride-induced liver.

Authors:  Chieko Aoyama; Akiko Ohtani; Kozo Ishidate
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

6.  Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of HepG2 cells.

Authors:  José M Jiménez-López; María P Carrasco; Josefa L Segovia; Carmen Marco
Journal:  Eur J Biochem       Date:  2002-09

7.  Selective killing of tumor cells by xanthates.

Authors:  E Amtmann; G Sauer
Journal:  Cancer Lett       Date:  1987-06       Impact factor: 8.679

8.  Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D.

Authors:  F Imamura; T Horai; M Mukai; K Shinkai; M Sawada; H Akedo
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

9.  Induction of choline kinase alpha by carbon tetrachloride (CCl4) occurs via increased binding of c-jun to an AP-1 element.

Authors:  Chieko Aoyama; Kozo Ishidate; Hiroyuki Sugimoto; Dennis E Vance
Journal:  Biochim Biophys Acta       Date:  2007-07-24

10.  Characterization of human PLD2 and the analysis of PLD isoform splice variants.

Authors:  P M Steed; K L Clark; W C Boyar; D J Lasala
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  298 in total

1.  In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model.

Authors:  Min-Hui Cui; Craig A Branch; Sean M Cahill; Thomas J Quinn; Asha Adem; Steven K Libutti; Ziqiang Yuan
Journal:  Magn Reson Med       Date:  2014-11-13       Impact factor: 4.668

2.  Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.

Authors:  Michael G Chiorazzo; Noah B Bloch; Anatoliy V Popov; Edward J Delikatny
Journal:  Bioconjug Chem       Date:  2015-10-28       Impact factor: 4.774

3.  Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses.

Authors:  Uma Kant Misra; Salvatore Vincent Pizzo
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

4.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 5.  MRI-only treatment planning: benefits and challenges.

Authors:  Amir M Owrangi; Peter B Greer; Carri K Glide-Hurst
Journal:  Phys Med Biol       Date:  2018-02-26       Impact factor: 3.609

6.  A New Role for the Mitochondrial Pro-apoptotic Protein SMAC/Diablo in Phospholipid Synthesis Associated with Tumorigenesis.

Authors:  Avijit Paul; Yakov Krelin; Tasleem Arif; Rina Jeger; Varda Shoshan-Barmatz
Journal:  Mol Ther       Date:  2017-12-24       Impact factor: 11.454

7.  Live-cell vibrational imaging of choline metabolites by stimulated Raman scattering coupled with isotope-based metabolic labeling.

Authors:  Fanghao Hu; Lu Wei; Chaogu Zheng; Yihui Shen; Wei Min
Journal:  Analyst       Date:  2014-05-21       Impact factor: 4.616

8.  Phospholipase D1 and choline kinase-α are interactive targets in breast cancer.

Authors:  Mayur Gadiya; Noriko Mori; Maria D Cao; Yelena Mironchik; Samata Kakkad; Ingrid S Gribbestad; Kristine Glunde; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

9.  Nanogel Carrier Design for Targeted Drug Delivery.

Authors:  D M Eckmann; R J Composto; A Tsourkas; V R Muzykantov
Journal:  J Mater Chem B       Date:  2014-12-14       Impact factor: 6.331

10.  Statins impair glucose uptake in tumor cells.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Jean-Francois H Geschwind
Journal:  Cancer Biol Ther       Date:  2012-12-19       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.